Sun Pharmaceutical Industries Ltd 2020 AR2
The report highlights Sun Pharmaceutical Industries Ltd.'s performance and strategic transformation during the 2019-2020 fiscal year. The company achieved a consolidated revenue growth of 13% to reach ’323 billion, driven by strong performance in India and its global specialty business. Sun Pharma expanded its specialty portfolio with the launch of CEQUA, ABSORICA LD, EZALLOR SPRINKLE, and DRIZALMA SPRINKLE in the US. Additionally, the company committed ’250 million in medicines and hand sanitisers to support India's COVID-19 response. It also invested ’43.71 million in various CSR initiatives, focusing on healthcare, education, and rural development.
Company: Sun Pharmaceutical Industries Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: AR2
Pages: 288
Back to company
Sun Pharmaceutical Industries Ltd
Annual Report
The report highlights Sun Pharmaceutical Industries Ltd.'s performance and strategic transformation during the 2019-2020 fiscal year. The company achieved a consolidated revenue growth of 13% to reach ’323 billion, driven by strong performance in India and its global specialty business. Sun Pharma expanded its specialty portfolio with the launch of CEQUA, ABSORICA LD, EZALLOR SPRINKLE, and DRIZALMA SPRINKLE in the US. Additionally, the company committed ’250 million in medicines and hand sanitisers to support India's COVID-19 response. It also invested ’43.71 million in various CSR initiatives, focusing on healthcare, education, and rural development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Employees